Drug Database
HP

HPV vaccine (walrinvax)

✓ Approved

Shanghai Zerun Biotechnology · 重组蛋白 · 重组蛋白

什么是 HPV vaccine?

HPV vaccine 是一种重组蛋白,由Shanghai Zerun Biotechnology研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名walrinvax
公司Shanghai Zerun Biotechnology
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

HPV vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPapilloma viral infection✓ Approved

相关研究文献

PubMedThe oncologist2026-11-19

Characteristics and Survival of Patients with Primary and Secondary Distant Metastasis of Oropharyngeal Squamous Cell Carcinoma (OPSCC).

McGarrah Patrick W PW, Agwaze Ruth N RN, O'Byrne Jamie J, Abdel-Halim Chadi C et al.

Approximately 20% of patients with oropharyngeal squamous cell carcinoma (OPSCC) develop distant metastases (DM). Survival outcomes after DM vary widely depending on clinical and biologic factors. This study compared baseline characteristics, management strategies, and oncologic outcomes among OPSCC patients with primary and secondary DM to better inform prognostication and therapeutic planning. We conducted a retrospective cohort study of patients treated at a tertiary care center with HPV/p16-positive, HPV/p16-negative, or unknown-status OPSCC who developed DM at any point. Treatments included surgery, radiation, and systemic therapy delivered with curative or non-curative intent. Cohort characteristics and overall survival (OS), stratified by primary versus secondary DM and treatment subgroups, were assessed using chi-square tests and Kaplan Meier analyses. A total of 132 patients were included: 18 with primary DM and 114 with secondary DM. HPV-positivity was lower in primary versus secondary DM group (22.2% vs 75.4%). Median follow-up was 32.4 months. Median OS from DM diagnosis was significantly shorter for primary versus secondary DM (9.6 vs 20.4 months; HR 2.00, 95% CI 1.16-3.46). Patients with secondary DM were more likely to receive metastasis-directed therapy (MDT). Median OS was 56.4 months with MDT and 13.2 months without (HR 0.38, 95% CI 0.23-0.61). This is the largest single center analysis of DM OPSCC to date. Primary DM OPSCC was associated with worse survival and lower HPV-positivity. Patients with DM, particularly those with HPV-positive disease, may achieve extended survival following aggressive treatment such as MDT.

PMID 43053275
阅读全文 →
PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedBMC cancer2026-11-19

Association of P53 and P16 expression with surgical and oncologic outcomes in vulvar squamous cell carcinoma: a retrospective cohort study.

Salameh Elias E, Kassis Nadine El NE, Tarchichi Samer S, Chakra Rim Abou RA et al.

The aim of this research is to evaluate the relationship between p53 and p16 expression and various clinicopathologic features, surgical interventions, and oncologic outcomes in patients diagnosed with vulvar squamous cell carcinoma (VSCC). We carried out a retrospective cohort study involving women treated for vulvar squamous cell carcinoma (FIGO stages I-IV) at Hôtel-Dieu de France in Beirut, Lebanon, from 2014 to 2024. Collected data included patient characteristics, surgical management, postoperative complications, pathological features, recurrence, and survival rates. Tumor specimens were analyzed for p53 and p16 expression using immunohistochemistry, and human papillomavirus (HPV) DNA was evaluated by vaginal PCR. Statistical analyses included Chi-square, Fisher's exact, and Mann-Whitney tests, with significance set at p < 0.05. A cohort of 125 patients was initially included in the analysis, of whom 86 underwent p53/p16 immunohistochemical evaluation: 38 were p53-positive, 15 were p16-positive, 33 were p53/p16-negative,14 out of 86 patients were HPV positive. In the p53-positive group, tumors were more often central, resulting in clitoral excision in all patients in this subgroup (p = 0.008). P53 positivity was associated with increased rates of inguinal lymph node metastasis (p < 0.001) and a higher number of metastatic lymph nodes excised (p = 0.001), and worse baseline Eastern Cooperative Oncology Group (ECOG) performance score (p = 0.04). Although depth of invasion tended to be greater in p53-positive tumors, this difference was not statistically significant. Postoperative complication rates, recurrence, and survival were comparable across biomarker groups. No significant association was observed between p16 expression, HPV status, or smoking history. In our cohort, p53-positive vulvar squamous cell carcinoma was associated with more aggressive clinicopathologic features, including increased nodal involvement and wider surgical resection due to midline tumor location. However, p53 expression was not associated with higher postoperative complication or recurrence rates. These findings suggest that while p53 may reflect tumor aggressiveness; its role in guiding surgical or prognostic decision-making requires further prospective evaluation.

PMID 43052862
阅读全文 →
PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedNPJ vaccines2026-11-19

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge.

Portela Catani João Paulo JP, Smet Anouk A, Ysenbaert Tine T, Amelinck Laura L et al.

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.

PMID 43052397
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多HPV vaccine